Valuation: Precipio Inc

Market Cap 3.87Cr 3.36Cr 3.13Cr 2.87Cr 5.43Cr 369.4Cr 5.51Cr 37Cr 14Cr 183.9Cr 15Cr 14Cr 616.66Cr P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 3.97Cr 3.45Cr 3.21Cr 2.95Cr 5.57Cr 378.96Cr 5.66Cr 38Cr 15Cr 188.67Cr 15Cr 15Cr 632.63Cr EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.35%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 01/06/2017
Chief Executive Officer 54 28/06/2017
Director TitleAgeSince
Director/Board Member 54 28/06/2017
Director/Board Member 78 26/09/2017
Director/Board Member 67 08/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 3.87Cr
-1.89%-1.36%+19.78%-40.36% 1.57TCr
+4.47%+7.46%+3.82%+107.97% 177.35Cr
+1.21%+4.49%-26.48%-80.29% 114.36Cr
-1.73%+2.33%-33.93%+16.19% 98Cr
+1.29%+7.31%-44.39%-52.50% 65Cr
+0.93%+7.41%-45.64%-53.16% 54Cr
+1.08%+2.47%+55.85%-51.37% 47Cr
-0.81%+1.33%-52.64%-61.03% 37Cr
-0.81%+5.14%-13.72%-32.63% 37Cr
Average +2.38%+2.54%-15.26%-27.46% 244.53Cr
Weighted average by Cap. -0.91%-0.19%+9.16%-29.10%

Financials

2024 2025
Net sales 1.85Cr 1.61Cr 1.5Cr 1.38Cr 2.6Cr 176.91Cr 2.64Cr 18Cr 6.94Cr 88Cr 6.96Cr 6.81Cr 295.32Cr 2.4Cr 2.09Cr 1.95Cr 1.79Cr 3.37Cr 229.57Cr 3.43Cr 23Cr 9Cr 114.29Cr 9.03Cr 8.83Cr 383.24Cr
Net income -42.9L -37.29L -34.71L -31.87L -60.18L -41Cr -61.12L -4.09Cr -1.61Cr -20Cr -1.61Cr -1.58Cr -68Cr -4L -3L -3L -3L -5L -3.47Cr -5L -34.62L -13.59L -1.73Cr -13.63L -13.33L -5.78Cr
Net Debt -1L -1L -1L -1L -2L -1.3Cr -2L -12.97L -5L -64.63L -5L -5L -2.17Cr 10.02L 9L 8L 7L 14.06L 9.57Cr 14.27L 95.57L 37.51L 4.76Cr 37.63L 36.8L 16Cr
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-